Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ponatinib hydrochloride
Find trials that include:  Any drugs shown
Results 1-9 of 9 for your search:
Start Over
Ponatinib Hydrochloride with or without Azacitidine in Treating Patients with FLT3-mutated Acute Myeloid Leukemia
Status: Not yet active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-1083, NCI-2016-01187, NCT02829840
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients with Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0030, NCI-2011-02941, NCT01424982
Ponatinib Hydrochloride in Treating Patients with Stage IIIB-IV Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-103, NCI-2013-01802, NCT01813734
Ponatinib Hydrochloride in Treating Patients with Stage III-IV Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-2002, NCI-2013-01644, PAM004-1, PAM005-2, NCT01935336
Ponatinib Hydrochloride in Treating Patients with Advanced Biliary Cancer with FGFR2 Fusions
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1345, NCI-2014-02075, NCT02265341
Ponatinib Hydrochloride in Treating Patients with Refractory Metastatic Cancers and Genetic Alterations
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14078, NCI-2014-01499, 14078, 2014C0143, NCT02272998
Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AP24534-14-203, NCI-2015-01086, 2014-001617-12, NCT02467270
Ponatinib Hydrochloride in Treating Patients with Bevacizumab-Refractory Glioblastoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-163, NCI-2015-01746, AP24534-13-020, NCT02478164
Personalized Kinase Inhibitor Therapy Combined with Chemotherapy in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 64
Trial IDs: IRB00011766, NCI-2016-00083, NCT02779283
Start Over